Yazar "Aydin, Suleyman" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Potassium Ion Channel Protein (KCNH) Levels in Patients with Fibromyalgia Syndrome
    (C M B Assoc, 2021) Tas, Ayca; Hayta, Emrullah; Karadag, Ahmet; Zontul, Cemile; Ozmen, Esma; Aydin, Suleyman; Silig, Yavuz
    Although there is not yet full clarity of the pathogenesis of fibromyalgia syndrome (FM), central sensitization is considered to be responsible. The purpose of this study was to measure the plasma levels of potassium ion channel proteins (human KCNH2, KCNH6 and KCNH7) in FM patients and healthy control subjects. The study sample includes 76 newly diagnosed FM patients and 79 healthy individuals. Venous blood samples were taken to measure the plasma levels of KCNH2, KCNH6 and KCNH7. Pain severity in FM patients was assessed using a visual analog scale (VAS). Bioinformatics analysis was performed using the STRING v 11 Protein interaction tool. Age, gender and body mass index were seen to be similar in both groups. In comparisons between FM and control groups, KCNH2 plasma levels was found to be significantly lower in the FM group. No significant correlation was found between plasma levels of KCNH2, KCNH6 and KCNH7 protein levels and VAS score of patients with FM. The KCNH2 protein had a high homology score with 9 proteins. The plasma levels of KCNH2 FM patients were found to be lower than those of the healthy control subjects, no difference was determined in respect of the plasma levels of KCNH6 and KCNH7. These results may be of use in guiding future studies on the pathogenesis of FM. Copyright: (c) 2021 by the C.M.B. Association. All rights reserved.
  • Küçük Resim Yok
    Öğe
    Serum and salivary obestatin concentrations in thediagnosis of polycystic ovary syndrome
    (2021) Yavuz, Adem; Aydin, Suleyman; Gurates, Bilgin
    Aim: : To measure obestatin levels in the blood and saliva samples of normal-weight patients with polycystic ovary syndrome(PCOS) in comparison with normal-weight healthy controls, and to determine whether there were relationships between blood and/or salivary obestatin levels and other measured parameters.Materials and Methods: Fifteen healthy women and 15 patients with PCOS, all of which had normal weight, were included in thestudy. Participants’ age, height, weight, menstrual characteristics, hormone levels, body mass index, waist/hip ratio, and modified Ferriman-Gallwey (FG) scores were recorded. Obestatin levels were measured in both fasting blood and saliva samples. Homeostasis Model Assessment (HOMA-IR) was used to predict insulin resistance.Results: In the PCOS group, menstrual cycle duration and FG scores were significantly higher (P-value, <0.001, <0.001, respectively).The levels of luteinizing hormone, total testosterone and androstenedione were significantly higher in the PCOS group than in the control group (P-value, 0.001, 0.009, 0.004, respectively). In the PCOS group, blood obestatin level was 1265.2 ± 221.9 pg/ml, salivary obestatin level was 3095.33 ± 310.2 pg/ml; whereas the control group demonstrated lower levels of 939.66 ± 72.3 pg/ml and 2611.20 ± 217.1 pg/mL, respectively. However, no statistically significant difference was found between the PCOS and control groups when comparing obestatin levels in blood or saliva (P-value, 0.218, 0.369, respectively). No correlation was found between blood and salivary obestatin levels in either group. Finally, obestatin levels were not associated with any of the other measured parameters.Conclusion: Our results suggest that increased levels of obestatin, albeit in a small amount that would not be statistically significantin normal weight patients with PCOS, may have significant effects on weight control in these patients. In addition, our findings show that saliva sample can be used as an alternative to blood sample in the measurement of obestatin level in patients with PCOS.